10:39 PM
 | 
May 11, 2017
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA grants Regeneron's evinacumab breakthrough therapy designation for HoFH

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) said FDA granted breakthrough therapy designation to evinacumab (REGN1500)...

Read the full 41 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >